GNMSF (Genmab AS) Short Interest


GNMSF Genmab AS GNMSF
95 GF Score
Price $257.44
GF Value $343.48
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Genmab AS Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

GNMSF vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Genmab AS's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genmab AS Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Short Interest distribution charts can be found below:

* The bar in red indicates where Genmab AS's Short Interest falls into.


GNMSF
95GF Score
Genmab AS GNMSF
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Genmab AS (GNMSF) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued. The current stock price of $257.44 is trading 25.1% below its estimated GF Value™ of $343.48. GuruFocus considers Genmab AS to be Modestly Undervalued.

Key valuation signals for GNMSF:

  • Short Interest:
  • GF Value™: $343.48 vs. price of $257.44 (25.1% below fair value)
  • GF Score™: 95/100 with 5 warning signs

No single metric tells the full story. See the GNMSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
95GF Score

Get the complete analysis for GNMSF

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$257.44
Price
$343.48
GF Value